Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.53% | 6.17% | 1.51% | -2.10% | -7.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.53% | 6.17% | 1.51% | -2.10% | -7.13% |
| Cost of Revenue | -8.33% | 50.39% | 50.74% | 56.08% | 51.72% |
| Gross Profit | 13.69% | -11.70% | -16.08% | -19.97% | -24.41% |
| SG&A Expenses | -6.22% | -5.15% | -11.14% | -16.15% | -19.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.00% | -3.75% | -11.22% | -32.18% | -42.62% |
| Operating Income | 6.57% | 9.58% | 18.19% | 43.71% | 53.42% |
| Income Before Tax | 42.10% | 41.72% | 57.26% | 24.31% | 35.98% |
| Income Tax Expenses | -100.30% | -102.74% | -105.68% | -106.22% | 4,337.31% |
| Earnings from Continuing Operations | 42.69% | 42.30% | 57.61% | 25.03% | 35.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.69% | 42.30% | 57.61% | 25.03% | 35.34% |
| EBIT | 6.57% | 9.58% | 18.19% | 43.71% | 53.42% |
| EBITDA | 4.35% | 7.48% | 16.62% | 43.92% | 54.47% |
| EPS Basic | 46.09% | 44.63% | 58.36% | 26.08% | 36.36% |
| Normalized Basic EPS | 10.43% | 14.53% | 23.99% | 38.70% | 50.60% |
| EPS Diluted | 46.18% | 44.72% | 58.41% | 26.17% | 36.26% |
| Normalized Diluted EPS | 10.43% | 14.53% | 23.99% | 38.70% | 50.60% |
| Average Basic Shares Outstanding | 6.17% | 4.06% | 1.90% | 1.53% | 1.60% |
| Average Diluted Shares Outstanding | 6.17% | 4.06% | 1.90% | 1.53% | 1.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
